Home Cart Sign in  
Chemical Structure| 30462-35-2 Chemical Structure| 30462-35-2

Structure of Theaflavin 3,3'-digallate
CAS No.: 30462-35-2

Chemical Structure| 30462-35-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Theaflavin 3,3'-digallate (TF-3) is an effective inhibitor of Zika virus (ZIKV) protease, with an IC50 of 2.3 μM. Theaflavin 3,3'-digallate directly binds to ZIKVpro (Kd=8.86 µM) and inhibits ZIKV replication. Theaflavin 3,3'-digallate inhibits the activity of gp41 and NS2B-3 proteases and exhibits antiviral activity against HSV and HIV-1. Theaflavin 3,3'-digallate is a typical pigment in black tea and an effective antitumor agent.

Synonyms: TF-3; ZP10; TFDG

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Theaflavin 3,3'-digallate

CAS No. :30462-35-2
Formula : C43H32O20
M.W : 868.70
SMILES Code : O=C(C1=CC(O)=C(O)C(O)=C1)O[C@H]2[C@H](OC3=CC(O)=CC(O)=C3C2)C4=C5C(C(C(O)=CC([C@@H]6[C@@H](CC7=C(O)C=C(O)C=C7O6)OC(C8=CC(O)=C(O)C(O)=C8)=O)=C5)=O)=C(O)C(O)=C4
Synonyms :
TF-3; ZP10; TFDG
MDL No. :MFCD06797365

Safety of Theaflavin 3,3'-digallate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 75 µM 1 hour To evaluate the antiviral activity of theaflavins against HSV-1, results showed that TF3 at 50 μM and above inhibited >99% of HSV-1 viral particle production. Antiviral Res. 2015 Jun;118:56-67
Vero cells 75 µM 1 hour To evaluate the antiviral activity of theaflavins against HSV-1, results showed that TF3 at 50 μM and above inhibited >99% of HSV-1 viral particle production. Antiviral Res. 2015 Jun;118:56-67
CV-1 cells 250-500 µM 1 hour Assess the inactivation effect of TF-3 on HSV-1 clinical isolates. Results indicated that some HSV-1 clinical isolates required higher concentrations of TF-3 (250-500 μM) to achieve comparable inactivation to HSV-2. Antimicrob Agents Chemother. 2013 Aug;57(8):3806-14
Vero cells 100 µM 1 hour Evaluate the efficacy of TF-3 combined with lactic acid (LA) in inactivating HSV-1 and HSV-2 at various pH levels. Results showed that TF-3 combined with LA almost completely inactivated clinical isolates of HSV-2 and HSV-1 at pH 4.5 to 5.7. Antimicrob Agents Chemother. 2013 Aug;57(8):3806-14
3T3-L1 adipocytes 3.14 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, 100 µM 10 days (Day 18 to Day 28) Theaflavin-3,3'-digallate (TF-3) reduced the impact of methylmercury by maintaining the adipocytes morphology and secretion patterns of adiponectin, resistin and 4-hydroxynonenal. TF-3 showed dose-dependent effects in counteracting methylmercury-induced oxidative stress and inflammation. Int J Mol Sci. 2019 Jun 5;20(11):2755
H9c2 cells 1-10 µM 24 hours Prevention of angiotensin II-induced pathological cardiac hypertrophy via inhibition of the CaN-NFAT signaling pathway Nutrients. 2022 Mar 26;14(7):1391
Peritoneal macrophages 40 µM 24 hours To evaluate the inhibitory effect of TFDG on NO production in LPS-activated macrophages. Results showed that TFDG downregulated NO production in a concentration-dependent manner, with maximal effect at 40 μM and no cytotoxicity observed. Br J Pharmacol. 2006 Sep;149(1):121-31
Human ovarian carcinoma cells OVCAR-3 10-20 µM 24 hours TF3 significantly reduced the viability of OVCAR-3 cells and induced apoptosis and G0/G1 cell cycle arrest. Molecules. 2019 Feb 14;24(4):673
Demineralized dentin collagen 12.5, 25, 50, 100 mg/mL 30 and 60 seconds TF3/ethanol solution could effectively crosslink demineralized dentin collagen and improve its resistance to collagenase digestion and biomechanical properties (p<0.05), showing concentration and time dependence. The effect of 25 and 50 mg/ml TF3/ethanol solution was similar to that of 5% GA, whereas the 100 mg/mL TF3/ethanol solution exhibited better performance (p<0.05). Front Bioeng Biotechnol. 2024 May 15;12:1401032
Rat aortic rings 0.02–2 µM 30 minutes To investigate the vasorelaxation induced by theaflavin-3,3'-digallate and its mechanism, it was found that it mediates NO-dependent vasodilation through the production of hydrogen peroxide (H2O2). Antioxidants (Basel). 2020 May 7;9(5):390
Rat aortic endothelial cells (RAECs) 0.5 μg/mL 30 minutes TF3 suppressed Hcy-induced ER stress markers (e.g., phosphorylated eIF2α, ATF3, and cleaved ATF6) and reduced ROS production. Sci Rep. 2015 May 15;5:10340
Rat aortic smooth muscle cells (RASMCs) 1, 10, 20 µM 48 hours To evaluate the effect of TF3 on PDGF-BB-induced migration in RASMCs. Wound healing and Transwell assays showed that TF3 inhibited PDGF-BB-induced migration in a concentration-dependent manner. Front Pharmacol. 2022 Jul 12;13:861319
Rat aortic smooth muscle cells (RASMCs) 1, 10, 20 µM 48 hours To evaluate the effect of TF3 on PDGF-BB-induced proliferation in RASMCs. EdU and CCK-8 assays showed that TF3 inhibited PDGF-BB-induced proliferation in a concentration-dependent manner. Front Pharmacol. 2022 Jul 12;13:861319
Rat aortic smooth muscle cells (RASMCs) 1, 10, 20 µM 48 hours To evaluate the effect of TF3 on PDGF-BB-induced phenotypic switching in RASMCs. Results showed that TF3 reversed the PDGF-BB-induced decrease in contractile proteins (MYH11, α-SMA, and SM22) in a concentration-dependent manner. Front Pharmacol. 2022 Jul 12;13:861319
Purified F1-ATPase 0.7 µM 5 minutes To evaluate the inhibitory effect of Theaflavin 3,3'-digallate on purified F1-ATPase, results showed an IC50 value of 0.7 μM and an inhibition rate of 90%. J Nutr Biochem. 2012 Aug;23(8):953-60
E. coli membrane vesicles 10-20 µM 5 minutes To evaluate the inhibitory effect of Theaflavin 3,3'-digallate on ATP hydrolysis, results showed an IC50 value of 10 μM and an inhibition rate of 90%. J Nutr Biochem. 2012 Aug;23(8):953-60
MC3T3-E1 cells 0.1 µM and 1 µM 7 days TFDG promotes the formation of osteoblasts and enhances their mineralization ability in inflammatory environment Front Pharmacol. 2021 Mar 23;12:648969

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish (Danio rerio) Alloxan-induced diabetic model Water solution treatment 0.5-20 μg/mL 24 hours To evaluate the hypoglycemic effect and mechanism of TF3 in diabetic zebrafish, results showed that TF3 could significantly reduce blood glucose levels by down-regulating PEPCK and up-regulating GCK expression, and promote β cells regeneration at low concentrations. Nutrients. 2021 Dec 7;13(12):4379
C57BL/6 mice Ovariectomy-induced osteoporosis model Injection 1 mg/kg and 10 mg/kg Every 2 days for 5 weeks TFDG significantly increased bone mass in ovariectomized mice, reduced the release of proinflammatory cytokines, and increased the expression of osteogenic markers Front Pharmacol. 2021 Mar 23;12:648969
DBA/1 mice Collagen-induced arthritis (CIA) model Intraperitoneal injection 1 mg/kg or 10 mg/kg 6 days a week for 8 weeks To investigate the effect of TFDG on CIA mice. Results showed that TFDG ameliorated joint destruction, reduced inflammatory cytokines, and promoted M2 macrophage polarization. J Inflamm Res. 2023 Jan 10;16:109-126
C57BL/6J female mice Ovariectomy (OVX)-induced osteoporosis model Intraperitoneal injection 1 mg/kg, 10 mg/kg Three times per week for 3 months To evaluate the effect of TF3 on OVX-induced bone loss. Results showed that TF3 significantly attenuated OVX-induced bone loss and osteoclastogenesis in a dose-dependent manner. Front Pharmacol. 2020 Jun 29;11:803
C57BL/6 mice Carotid artery ligation model Intraperitoneal injection 10 mg/kg Injected one day before surgery and repeated every other day for 14 or 28 days To evaluate the effect of TF3 on carotid artery ligation-induced neointimal hyperplasia. Results showed that TF3 significantly reduced the intima-to-media ratio (I/M ratio) and increased lumen diameter and area. Front Pharmacol. 2022 Jul 12;13:861319
Chicken embryos Chick chorioallantoic membrane (CAM) model Implanted onto the CAM 25 µM Single administration, lasting for 5 days To evaluate the inhibitory effect of TF3 on tumor angiogenesis in vivo, results showed that TF3 significantly reduced blood vessel density. Int J Oncol. 2016 Jan;48(1):281-92
Mice Leptin-deficient obese (ob/ob) mice Intraperitoneal injection 5 mg/kg, 10 mg/kg, 20 mg/kg Once daily for 4 weeks TF3 treatment prevented body weight and waistline gain, reduced lipid accumulation, and alleviated liver function injury, as well as decreased serum lipid levels and TG levels in livers. Front Pharmacol. 2022 Aug 29;13:925264
BALB/c mice TNBS-induced colitis model Oral gavage 5 mg/kg/day Once daily for 18 days To evaluate the protective effect of TFDG on TNBS-induced colitis. Results showed that TFDG significantly improved macroscopic and microscopic damage scores, reduced neutrophil infiltration, decreased mRNA and protein levels of proinflammatory cytokines (TNF-α, IL-12, IFN-γ) and iNOS, and preserved IκBα by inhibiting IKK activity and nuclear translocation of NF-κB. Br J Pharmacol. 2006 Sep;149(1):121-31
BALB/c mice S aureus pneumonia model Hypodermic injection 50 mg/kg TFDG, 15 mg/kg cephalothin Every 12 hours for 72 hours Evaluate the protective effect of TFDG combined with cephalothin against S aureus pneumonia in mice, showing that the combination significantly reduced mortality and alleviated lung pathological changes. J Cell Mol Med. 2019 Oct;23(10):6955-6964

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.15mL

0.23mL

0.12mL

5.76mL

1.15mL

0.58mL

11.51mL

2.30mL

1.15mL

 

Historical Records

Categories